Skip to Content
Merck
CN

SML3336

VU0155056

≥98% (HPLC)

Synonym(s):

5W0, ML272, N-(2-{4-[2-Oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}ethyl)-2-naphthamide, N-[2-[4-(2,3-Dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide, VU 0155056

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C25H26N4O2
CAS Number:
Molecular Weight:
414.50
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Catalytic site-targeting dual phospholipase D1 & D2 (PLD1 & PLD2) inhibitor.
VU0155056 is a catalytic site-targeting phospholipase D inhibitor (PLD1/PLD2 IC50 = 81 nM/240 nM by cell-free enzymatic assays; substrate = di-palmitoyl-PLC) that effectively suppresses the cellular PLD activity in GFP-PLD2-overexpressing HEK293 cells as well as PMA-stimulated non-small-cell lung cancer (NSCLC) Calu-1 cells with predominant PLD1 activity (IC50 = 380 nM and 21 nM, respectively).


Still not finding the right product?

Explore all of our products under VU0155056


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Jeffrey L Barr et al.
International journal of molecular sciences, 22(10) (2021-06-03)
Orexin A, an endogenous peptide involved in several functions including reward, acts via activation of orexin receptors OX1 and OX2, Gq-coupled GPCRs. We examined the effect of a selective OX1 agonist, OXA (17-33) on cytosolic calcium concentration, [Ca2+]i, in neurons
Amanda R Noble et al.
British journal of cancer, 121(12), 1016-1026 (2019-11-02)
Phospholipases D1 and D2 (PLD1/2) are implicated in tumorigenesis through their generation of the signalling lipid phosphatidic acid and its downstream effects. Inhibition of PLD1 blocks prostate cell growth and colony formation. Here a role for PLD2 in prostate cancer
Mukesh Kumar et al.
The Journal of cell biology, 218(11), 3697-3713 (2019-10-13)
Triglyceride-rich lipid droplets (LDs) are catabolized with high efficiency in hepatocytes to supply fatty acids for producing lipoprotein particles. Fasting causes a massive influx of adipose-derived fatty acids into the liver. The liver in the fasted state is therefore bloated



Global Trade Item Number

SKUGTIN
SML3336-25MG04065268975060
SML3336-5MG04065268975077